Abstract
Objective To derive robust estimates for the cost of multiple sclerosis (MS) based on a variety of cost factors across a number of different cost perspectives. This is essential to perform credible pharmacoeconomic evaluations of alternative MS therapies. Methods Here we present a detailed analysis of previously published MS cost data for the UK to which we fit a seemingly unrelated regression. This allows us to assess the size and significance of different cost factors, and account for the covariance between cost perspectives. Results We show that disability severity, disease type, relapse status, treatment type and time of treatment, sex, age, educational status, and time since diagnosis, are significant cost factors, with the significance of each dependent on the cost perspective chosen. Conclusion This analysis provides a statistical model that may be used to better estimate individual patient costs across a range of demographic and cost perspectives, for use by health planners and in pharmacoeconomic evaluations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
